/
Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammati…
The business is unprofitable at the operating level (-279.49% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 36.8% YoY with margins expanding 174.8pp.
Negative free cash flow of -$86M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$28M
▲ +36.8% YoY
Net Income (TTM)
-$75M
▲ +14.2% YoY
Op. Margin
-301.34%
▲ +174.8pp YoY
ROIC
-207.55%
▲ +23.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$87M
▲ +15.0% YoY
Op. Cash Flow (TTM)
-$87M
▲ +14.2% YoY
Net Debt
-$46M
Net Cash Position
Cash & Equiv.
$88M
5Y CAGR: +135.1%
Continue Research